Health · 1 sources covering this

STAT+: The latest orphan drug exemptions may not be warranted, analysis finds

A new analysis questions the wisdom of a controversial provision in federal law that exempts so-called orphan drugs from Medicare pricing negotiations.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: The latest orphan drug exemptions may not be warranted, analysis finds
A new analysis questions the wisdom of a controversial provision in federal law that exempts so-called orphan drugs from Medicare pricing negotiations.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/ce15b2f91563ee9f820e8e0a9d83cea6df04791a"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: The latest orphan drug exemptions may not be warranted, analysis finds"></iframe>

STAT+: The latest orphan drug exemptions may not be warranted, analysis finds

How 1 sources are covering this

STAT+: The latest orphan drug exemptions may not be warranted, analysis finds

More from Health

STAT+: Are AI scribes medical devices? UK regulator weighs in.

STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more

Trans federal employees sue over revoked health coverage

They're a world leader in using drones for healthcare. But drones can't do it all

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: The latest orphan drug exemptions may not be warranted, analysis finds

More from Health

STAT+: Are AI scribes medical devices? UK regulator weighs in.

STAT+: Pharmalittle: We&#8217;re reading about a Lilly access program, a Gilead court victory, and more

Trans federal employees sue over revoked health coverage

They're a world leader in using drones for healthcare. But drones can't do it all

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more